EVAXION_DEEPBLUE_RGB.png
Evaxion establishes new AI-derived precision cancer vaccine concept
12 déc. 2024 08h00 HE | Evaxion Biotech
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...
EVAXION_DEEPBLUE_RGB.png
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
02 déc. 2024 08h00 HE | Evaxion Biotech
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...
image1 (1).png
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
26 juin 2024 07h30 HE | Evaxion Biotech
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the inventionUnique Attributes and...
EVAXION_BLACK_RGB.jpg
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
28 mars 2023 07h46 HE | Evaxion Biotech
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...
EVAXION_BLACK_RGB.jpg
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
23 mars 2023 07h55 HE | Evaxion Biotech
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to...